Danaher Corporation $DHR Shares Newly Acquired by William Allan Corp

William Allan Corp bought a new position in shares of Danaher Corporation (NYSE:DHR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,275 shares of the conglomerate’s stock, valued at approximately $2,055,000. Danaher makes up approximately 1.1% of William Allan Corp’s investment portfolio, making the stock its 27th largest position.

Several other hedge funds have also recently modified their holdings of DHR. Mather Group LLC. lifted its position in shares of Danaher by 921.1% in the third quarter. Mather Group LLC. now owns 125,665 shares of the conglomerate’s stock valued at $27,841,000 after acquiring an additional 113,358 shares in the last quarter. First Pacific Financial boosted its stake in shares of Danaher by 5.3% in the third quarter. First Pacific Financial now owns 3,465 shares of the conglomerate’s stock worth $768,000 after acquiring an additional 175 shares during the last quarter. MPS Loria Financial Planners LLC boosted its stake in shares of Danaher by 46.0% in the third quarter. MPS Loria Financial Planners LLC now owns 7,656 shares of the conglomerate’s stock worth $1,696,000 after acquiring an additional 2,413 shares during the last quarter. Cliftonlarsonallen Wealth Advisors LLC purchased a new stake in shares of Danaher during the third quarter worth approximately $2,953,000. Finally, Meridian Investment Counsel Inc. purchased a new stake in shares of Danaher during the third quarter worth approximately $842,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.8%

DHR opened at $224.65 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company’s 50 day simple moving average is $212.92 and its two-hundred day simple moving average is $195.39. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The firm has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 EPS. Analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DHR shares. The Goldman Sachs Group increased their price objective on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research note on Monday, September 21st. UBS Group assumed coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Royal Bank Of Canada upped their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Finally, Guggenheim upped their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.